Skip to main content
. Author manuscript; available in PMC: 2024 Mar 1.
Published in final edited form as: Oncogene. 2018 Apr 6;37(27):3672–3685. doi: 10.1038/s41388-018-0156-9

Table 2.

Pharmocokinetics

Compound Route C0/Cmax (ng/mL) AUClast (hr×ng/mL) AUCinf (hr×ng/mL) T1/2 (hr) CL (mL/min/kg) Vss (L/kg)
DMH2(2) i.v. 3,035 485 487 0.95 68 0.95
p.o. 684 707 729
JL5 i.v. 568 349 381 0.57 194 8.78
p.o. 1,282 1,605 1,645

From: Novel bone morphogenetic protein receptor inhibitor JL5 suppresses tumor cell survival signaling and induces regression of human lung cancer